Diasorin S.p.a. · MIL:DIA

Diasorin — Investor Day (2026)

11 slides from Diasorin's investor day presentation, Sep 30, 2026

  1. Slide 1: ESG & Financials

    06 ESG & FINANCIALS Alberto Donati

  2. Slide 2: ESG

    E S G Sma ( PASSIONE PER IA ( PASSIONE a SCIENZA, PER LA SCIENZA PERL ; 3 LEGS : ft tigers H : | 4. fe: aly Pes h a" . \ y

  3. Slide 3: ESG 2026-2030

    06 | ESG & FINANCIALS ESG ESG 2026-2030 OBJECTIVES KPIs E Improve Group’s energy efficiency -600 tons of CO₂ in industrial sites by 2030 Strengthen Diversity & Inclusion 100% of employees trained on D&I Enhance employee wellbeing ≥80% of Group employees covered by employee assistance programs S Prom

  4. Slide 4: Financials

    FINANCIALS

  5. Slide 5: Guidance @CER: Total Revenues

    06 | ESG & FINANCIALS Guidance | Total Revenues Guidance @CER*: Total Revenues +6% / +8% CAGR +5% / +6% 2025 A 2026 Estimate 2030 Estimate * In order to allow comparability across years, all financials' data have been restated at constant exchange rate (with regard to the U.S. dollar 1.20 USD per EU

  6. Slide 6: Revenues By Technology @CER

    06 | ESG & FINANCIALS Guidance | Revenues by Technology Revenues By Technology @CER* +6% / +8% Licensed Technologies CAGR Molecular Diagnostics Low-to-Mid Single Digit Immunodiagnostics Increase +5% / +6% LIAISON NES > 150 $/mln in the U.S. market Low-to-Mid Single High Teens Increase Digit Increase

  7. Slide 7: Revenues By Geography @CER

    06 | ESG & FINANCIALS Guidance | Revenues by Geography Revenues By Geography @CER* +6% / +8% Rest of the World CAGR Europe Mid-to-High Single Digit North America Increase +5% / +6% Low-to-Mid Single Digit Increase Flat Low-to-Mid Single Digit Increase Low Double Digit Increase High Single Digit Incr

  8. Slide 8: Revenues Evolution: from 2026 to 2030

    06 | ESG & FINANCIALS Guidance | Revenues Evolution Revenues Evolution: from 2026 to 2030 BY TECHNOLOGY 13% 10% Immunodiagnostics Immunodiagnostics 17% Molecular Diagnostics 2026 Licensed Technologies 2030 30% Molecular Diagnostics Licensed Technologies 60% 70% BY GEOGRAPHY 13% 10% Rest of the World

  9. Slide 9: Adjusted EBITDA Margin and Cumulated FCF

    06 | ESG & FINANCIALS Guidance | Adjusted EBITDA Margin and Cumulated FCF Guidance @CER*: Adjusted** EBITDA Margin and Free-Cash-Flow Cumulated FCF*** over 4 years Adjusted EBITDA Margin (2027-2030) ca. +200 bps 34% - 35% ~ 1 €/bn 32% 32% - 33% / 33% 34% / 35% 2026 Estimate 2030 Estimate * In order

  10. Slide 10: Capital Allocation Strategy

    06 | ESG & FINANCIALS Capital Allocation Strategy Strong Operating Cash Flow Generation and Disciplined Capital Deployment to Maximise Shareholder Value FY 23-26 FY 27-30 Investment Amount / % of Total % of Total 1 Organic Growth Continue investing in the business in support of long-term organic gro

  11. Slide 11: Slide 11

Diasorin — Investor Day (2026) on 6ix